Journal article
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Abstract
BACKGROUND & AIMS: Although off-label use of sofosbuvir-containing regimens occurs regularly in patients with hepatitis C virus (HCV) infection undergoing dialysis for severe renal impairment or end-stage renal disease (ESRD), these regimens are not licensed for this indication, and there is an absence of dosing recommendations in this population. This study evaluated the safety and efficacy of sofosbuvir/velpatasvir in patients with HCV …
Authors
Borgia SM; Dearden J; Yoshida EM; Shafran SD; Brown A; Ben-Ari Z; Cramp ME; Cooper C; Foxton M; Rodriguez CF
Journal
Journal of Hepatology, Vol. 71, No. 4, pp. 660–665
Publisher
Elsevier
Publication Date
October 2019
DOI
10.1016/j.jhep.2019.05.028
ISSN
0168-8278